EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta‐Analysis

Ngozi C Chidi-Egboka iD, Leo Fan iD, Maria Qureshi iD, Chameen Samarawickrama iD, Fiona Stapleton iD, Tanya Trinh iD, Maria Markoulli iD, Elsie Chan, Jern Yee Chen, Jason Holland, Stephanie L Watson iD

Clinical & Experimental Ophthalmology · 2025

DOI: 10.1111/ceo.14514 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical & Experimental Ophthalmology, 2025. Verfasst von Ngozi C Chidi-Egboka und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Cyclosporine, Immunosuppressive Agents, Dry Eye Syndromes, Corneal Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSRD VA, Seqirus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To identify evidence on the use of topical CsA for ocular surface diseases (OSD).

Methods

A literature search was conducted following the preferred reporting items for systematic reviews and meta‐analyses (PRISMA) through June 2023 via Cochrane Central Registries, Clinical Trials Registry, Grey literature and citation searching. Randomised clinical trials (RCTs) in which different concentrations of topical CsA were compared with one another or other topical therapies were included. Risk of bias was assessed following the Cochrane ROB2 standard tool. Meta‐analysis was considered when data were sufficient. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE).

Results

Five hundred and eight‐three RCT publication titles were identified, of which 48 OSD RCTs were included. Thirty trials found significantly better efficacy with CsA irrespective of dose or concentration for OSD. The effect of CsA was comparable to artificial tears (AT), vehicle, fluorometholone 0.1%, tacrolimus 0.03% or diquafosol 3% only in 13 trials. Improved outcomes with CsA for symptoms (RCTs comprising 1107‐patients) and clinical signs, including in ocular surface staining (2505‐patients) and the average number of goblet cells (138‐patients) were found. Inconsistency of treatment effect on symptoms and signs, particularly tear film function, was evident in some trials. Ten trials were judged to be at high risk of bias. The certainty of evidence was judged to be low to moderate, downgraded mostly for imprecision and risk of bias.

Conclusions

Topical CsA treatment effect on ocular surface symptoms and staining suggests that CsA may be superior to the vehicle, AT or other topical treatment alternatives for OSD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclosporineImmunosuppressive AgentsDry Eye SyndromesCorneal DiseasesHumansOphthalmic SolutionsAdministration, TopicalRandomized Controlled Trials as TopicAdministration, Ophthalmic

Stichwörter der Autor:innen

dry eyeocular surface diseaseocular surface stainingsymptomstopical ciclosporin

Substanzen

CyclosporineOphthalmic SolutionsImmunosuppressive Agents

Autor:innen und Institutionen

  • Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, Clinical Ophthalmology and Eye Health, Westmead Institute for Medical Research (WIMR), save Sight Institute, Westmead and Central Clinical Schools, the University of Sydney, Sydney, Austr…
  • School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
  • Mosman Eye Centre, Mosman, New South Wales, Australia.
  • The Royal Victorian Eye & Ear Hospital, Centre for Eye Research Australia, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Ophthalmology, Flinders Medical Centre, Bedford Park, Australia.

ORCID-Profile: Ngozi C Chidi-Egboka, Leo Fan, Maria Qureshi, Chameen Samarawickrama, Fiona Stapleton, Tanya Trinh, Maria Markoulli, Stephanie L Watson

Förderung

  • CSRD VA
  • Seqirus

Zitieren

APA

Chidi-Egboka, N. C., Fan, L., Qureshi, M., Samarawickrama, C., Stapleton, F., Trinh, T., Markoulli, M., Chan, E., Chen, J. Y., Holland, J., & Watson, S. L. (2025). Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta‐Analysis. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/ceo.14514

Vancouver

Chidi-Egboka NC, Fan L, Qureshi M, Samarawickrama C, Stapleton F, Trinh T, et al. Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta‐Analysis. Clinical & Experimental Ophthalmology. 2025. doi:10.1111/ceo.14514

BibTeX
@article{ChidiEgboka2025,
  author = {Chidi-Egboka, Ngozi C and Fan, Leo and Qureshi, Maria and Samarawickrama, Chameen and Stapleton, Fiona and Trinh, Tanya and Markoulli, Maria and Chan, Elsie and Chen, Jern Yee and Holland, Jason and Watson, Stephanie L},
  title = {Evidence on the Use of Topical Ciclosporin for Ocular Surface Disease: A Systematic Review and Meta‐Analysis},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2025},
  doi = {10.1111/ceo.14514}
}
Kostenlos starten →